Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10435015" target="_blank" >RIV/00216208:11110/21:10435015 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/21:10435015
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=hzOO.lPWHf" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=hzOO.lPWHf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/diagnostics11122230" target="_blank" >10.3390/diagnostics11122230</a>
Alternative languages
Result language
angličtina
Original language name
Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
Original language description
Background: There is a lack of knowledge about the evolution of cerebrospinal fluid (CSF) markers in multiple sclerosis (MS) patients undergoing natalizumab treatment. Aim: We aimed to evaluate the effect of natalizumab on basic inflammatory CSF and MRI measures. Methods: Together, 411 patients were screened for eligibility and 93 subjects with >=2 CSF examinations <=6 months before and >=12 months after natalizumab initiation were recruited. The effect of natalizumab on CSF as well as clinical and paraclinical measures was analyzed using adjusted mixed models. Results: Natalizumab induced a decrease in CSF leukocytes (p < 1 x 10-15), CSF protein (p = 0.00007), the albumin quotient (p = 0.007), the IgG quotient (p = 6 x 10-15), the IgM quotient (p = 0.0002), the IgG index (p = 0.0004), the IgM index (p = 0.003) and the number of CSF-restricted oligoclonal bands (OCBs) (p = 0.0005). CSF-restricted OCBs positivity dropped from 94.6% to 86% but 26 patients (28%) had an increased number of OCBs at the follow-up. The baseline to follow-up EDSS and T2-LV were stable; a decrease in the relapse rate was consistent with a decrease in the CSF inflammatory markers and previous knowledge about the effectiveness of natalizumab. The average annualized brain volume loss during the follow-up was -0.50% (IQR = -0.96, -0.16) and was predicted by the baseline IgM index (B = -0.37; p = 0.003). Conclusions: Natalizumab is associated with a reduction of basic CSF inflammatory measures supporting its strong anti-inflammatory properties. The IgM index at the baseline predicted future brain volume loss during the course of natalizumab treatment.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
<a href="/en/project/NV18-04-00168" target="_blank" >NV18-04-00168: Complex characteristics of spinal cord pathology on MRI and its correlation with clinical disability and serum neurofilament levels in multiple sclerosis patients</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Diagnostics [online]
ISSN
2075-4418
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
12
Country of publishing house
CH - SWITZERLAND
Number of pages
12
Pages from-to
2230
UT code for WoS article
000736585300001
EID of the result in the Scopus database
2-s2.0-85121612507